Treatment of Candida glabrata cystitis remains a therapeutic challenge, and an antifungal combination using flucytosine is one option. We describe two patients with refractory C. glabrata cystitis who failed flucytosine combined with caspofungin with early-acquired high-level resistance to flucytosine due to nonsense mutations in the FUR1 gene. Rapidly acquired flucytosine resistance with microbiological failure should discourage combination of caspofungin and flucytosine during urinary candidiasis.
C
andiduria is a therapeutic challenge. Current recommendations mostly rely on fluconazole, and options against intrinsically fluconazole-less-susceptible or -resistant species like Candida glabrata are limited (1) . Whereas echinocandins exert a high fungicidal effect on Candida spp., their use in this setting remains unclear (2) . They display poor glomerular filtration and tubular secretion, with only 1% of the drug excreted unchanged, whereas fluconazole and flucytosine achieve high urine concentrations (10 to 100 times the serum levels) (3). Limited observations have, however, reported successful echinocandin-based treatments during candiduria (4) . Flucytosine also displays excellent activity against most Candida species, except C. krusei. High rates of acquired resistance during monotherapy are considered its major limitation and argue for systematic combination therapy, such as that with an azole, amphotericin B, or one echinocandin.
Here, we describe two patients with refractory C. glabrata cystitis who received caspofungin and flucytosine with early emergence of high-level flucytosine resistance caused by a stop codon in the FUR1 gene and microbiological failure.
Case 1.
A 66-year-old woman presented with symptomatic C. glabrata cystitis. She had undergone a kidney transplantation 1 month before but had no kidney abscess or urine retention. Blood cultures remained negative. The initial isolate was susceptible to caspofungin and flucytosine with the following MIC values (Etest; bioMérieux, Marcy l'Etoile, France): flucytosine, 1  A96G  G369C  R32R  V123V  A96G  G369C  R32R  V123V  T117C  T468C  S39S  C156C  T117C  T468C  S39S  C156C  G178G  A915G  WT  L305L  Ins 178-207  A915G  V61Stop  L305L  T355C  L119L  T355C  L119L  C370T  L124L  C370T  L124L  T528C  D176D  T528C  D176D   2  T355C  A693G  L119L  R231R  T355C  A693G  L119L  R232R  G368G  C813T  WT  A271A  G368T  C813T  E122Stop  A271A  C370T  G1008A  L124L  V336V  C370T  G1008A  L124L  V336V  T528C  C1425T  D176D  S475S  T528C  C1425T  D176D  S475S  T1530A  P510P  T1530A  P510P a Underlined text indicates nucleic acid changes within FUR1 and FCY2 genes compared to the sequences of the reference strain CBS138. Boldface text indicates amino acid changes that occurred as a result of sequence insertion or nucleic acid mutation within the FUR1 gene. WT, wild type. Specifically, no colony evocative of a flucytosine-resistant subpopulation was evidenced in the inhibition ellipse of the Etest. She received caspofungin (70 mg at day 1 and then 50 mg/day) for 3 weeks, and then flucytosine was added (50 mg/kg/day, according to creatinine clearance) for 3 subsequent weeks because of caspofungin monotherapy failure. The flucytosine serum peak concentration at day 10 was within the therapeutic range (49 mg/ liter). Treatment was stopped because of persisting symptoms and microbiological failure. The C. glabrata isolate collected at day 6 of flucytosine treatment and at treatment completion was resistant to flucytosine (MIC of 32 mg/liter without an increase in the caspofungin MIC).
Strains collected before introduction of flucytosine and at day 6 of flucytosine treatment were sequenced for FCY1, FCY2, and FUR1, encoding, respectively, a cytosine permease, a cytosine deaminase, and a uracil phosphotransferase-three genes often exhibiting mutations leading to flucytosine resistance (5) . Sequence analysis of the three genes in the initial wild isolate revealed the presence of a number of silent polymorphisms in FUR1 and FCY2 compared to the reference genome CBS138 (Table 1 ) (6). The same polymorphisms were found in the resistant strain that further displayed a 29-bp insertion within FUR1, creating a frameshift and a premature Stop codon, yielding a truncated protein (Fig. 1) . This insertion is the result of a 29-bp duplication, probably by slippage between two short repeated sequences (Fig.  1) (7) . Furthermore, isolates collected before and after flucytosine treatment showed identical multilocus sequence type (MLST) profiles (8) .
Case 2. A 65-year-old man presented with C. glabrata cystitis. His history included retroperitoneal fibrosis with obstructive chronic kidney disease requiring a double-J catheter (creatinine clearance, 35 ml/min). He had no kidney/prostatic abscess or urine retention. Blood cultures were negative. The strain was susceptible to caspofungin and flucytosine, with MIC values (Etest) as follows: flucytosine, 0.047 mg/liter; amphotericin B, 0.25 mg/ liter; fluconazole, 64 mg/liter; voriconazole, 1 mg/liter; and caspofungin, 0.06 mg/liter. Here again, no colony evocative of a flucytosine-resistant subpopulation was evidenced in the inhibition ellipse of the Etest. He received caspofungin (150 mg/day, in accordance to the dosage evaluated by Betts et al.) plus flucytosine (50 mg/kg/day according to creatinine clearance) for 4 weeks. The peak flucytosine serum concentration at day 4 was 57 mg/liter (9) . Urine culture performed 10 days after antifungal initiation yielded C. glabrata with acquired resistance to flucytosine. The MIC values were as follows: flucytosine, 32 mg/liter; and caspofungin, 0.125 mg/liter. The strain collected before introduction of flucytosine was sequenced as described before and exhibited silent polymorphisms in FUR1 and FCY2 compared to the reference strain ( Table 1 ). The resistant strain displayed the same polymorphisms but had one extra nonsense mutation within FUR1, creating a premature Stop codon and hence giving rise to a truncated protein ( Table 1) . As observed in case 1, both the strains collected prior to and after flucytosine treatment shared the same specific MLST profile.
Overall, the following important conclusions can be drawn from these observations. (i) These two patients had no concomitant condition that might have explained treatment failure: there was no upper tract infection or parenchymal abscess, urine obstruction, or fungemia. Both received caspofungin/oral flucytosine at standard or even high doses, and both had flucytosine peak concentrations in the therapeutic range. Treatment failure highlights that caspofungin at a standard dose (50 mg/day) or high dose (150 mg/day) did not achieve the clearance of C. glabrata in the urine of patients with refractory fungal cystitis. This is in accordance with previous data evidencing reduced fungicidal effect of echinocandins toward C. glabrata (10) .
(ii) Failure to eradicate infection was probably the consequence of the reported low urine excretion of caspofungin, although no urinary therapeutic drug monitoring was performed (2) . Indeed, in both cases caspofungin could not prevent the acquisition of flucytosine resistance that is bound to occur under monotherapy, knowing that the initial and subsequent C. glabrata isolates shared the same MLST profile in each patient, suggesting they were isogenic (11) .
(iii) In these two cases, high-level resistance to flucytosine is likely due to the acquisition of a Stop codon in the FUR1 gene, through two different mechanisms: duplication of sequence resulting in a frameshift (patient 1) and point mutation (patient 2). Previous reports suggest that high-level flucytosine resistance in clinical isolates is conferred by a wide array of point mutations conferring null phenotypes for Fcy1 or Fur1 (5, 12). Here we reported a new mechanism involving insertion of DNA fragment within the FUR1 gene, probably due to replication error through slippage between two short repeated sequences leading to a premature Stop codon. This mechanism led to the fast acquisition of flucytosine resistance in vivo. To our knowledge this had never been reported in the context of concomitant echinocandin prescription so far and never in such a small time interval: previous observations indeed reported acquired resistance 1 to 6 months after the treatment's initiation (12, 13, 14) . Altogether, these two observations advocate against the use of caspofungin and flucytosine combinations for the treatment of C. glabrata cystitis.
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